Covid-19, the Pfizer-Biontech vaccine is effective in more than 90% of cases

Pfizer and Biontech's vaccine prevents over 9 out of 10 Covid infections - a high threshold. Pfizer has just announced that it intends to ask the FDA for emergency authorization shortly and produce the first doses. What we know

(photo: Pixabay) One of the vaccines against the new coronavirus, developed by the manufacturers Pfizer and Biontech, is effective in preventing more than 90% of Covid-19 infections. The results come from phase 3 of the clinical trials, the last stage of the clinical trial. Pfizer president Albert Bourla just announced it. And, if all goes as hoped (remember, however, that it is difficult to make predictions) the company could produce 50 million doses of the vaccine in 2020 and up to 1.3 billion in 2021 - the data refer to production and this does not necessarily mean that we will have the vaccine at the end of the year.

The study

The researchers involved more than 43,000 participants, of which nearly 40,000 received the second dose as of November 8 and among which there were a total of 94 cases of Covid-19 infection. The first results indicate that the vaccine is effective in more than 9 out of 10 cases, that is, it manages to avoid infection in more than 90% of the people who received it. There have been no serious adverse reactions and the vaccine is well tolerated.

The data on efficacy continue to be collected: the investigation will not be complete until 164 cases of coronavirus infection are reached, so it's not finished yet. The companies indicate that within a short time they plan to submit the documents to the appropriate authorities - specifically the US Food and Drug Administration (FDA) - for an emergency authorization, also required in other cases during the pandemic.